Biosig Technologies (BSGM) Stock Price, News & Analysis

Company Overview

Biosig Technologies, Inc. is a clinical-stage medical device company developing advanced signal acquisition and processing systems for interventional electrophysiology. Its lead product, the PURE EP™ System, is designed to enhance the quality and reliability of intracardiac recordings during diagnostic and therapeutic procedures for cardiac arrhythmias, including atrial fibrillation and other rhythm disorders.

The PURE EP™ System integrates proprietary hardware and software to deliver higher-fidelity electrograms, helping physicians distinguish true cardiac signals from noise. Biosig Technologies is collaborating with electrophysiology labs and research institutions across the United States to conduct clinical studies and support regulatory filings aimed at expanding market access for its platform.

Founded in the early 2010s and headquartered in New York, Biosig Technologies has pursued U.S. Food and Drug Administration (FDA) regulatory clearance for its flagship device and initiated preparations for European CE mark registration. The company’s pipeline also includes software upgrades and ancillary tools intended to further improve procedural workflows and patient outcomes.

Under the leadership of President and Chief Executive Officer Kenneth L. Londoner, Biosig Technologies is positioning its PURE EP™ platform to address unmet needs in the growing field of cardiac rhythm management. By offering enhanced signal clarity and analytic capabilities, the company aims to become a preferred partner for electrophysiologists seeking innovative technologies to optimize interventional procedures.

Key Stats

• Today's Range: $4.36 to $6.12
• 50-Day Range: $3.68 to $6.35
• 52-Week Range: $0.59 to $14.11
• Volume: 3.10 million shs
• Average Volume: 1.08 million shs
• Market Capitalization: $199.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Buy

Company Calendar

• Last Earnings: 8/15/2025
• Today: 5/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:BSGM
• CIK: 1530766
• Web: www.biosig.com
• Phone: (230) 409-5444
• Fax: N/A
• Employees: 50
• Year Founded: 2009

Price Target and Rating

• Average Price Target for Biosig Technologies: $10.00
• High Price Target: $10.00
• Low Price Target: $10.00
• Potential Upside/Downside: +57.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.33 million
• Net Margins: N/A
• Pretax Margin: -201,392.33%
• Return on Equity: -5,336.99%
• Return on Assets: -90.03%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.03
• Quick Ratio: 0.03

Sales & Book Value

• Annual Sales: $13 thousand
• Price / Sales: 15,334.89
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.09) per share
• Price / Book: -70.50

Miscellaneous

• Outstanding Shares: 31,419,000
• Free Float: 23,627,000
• Market Cap: $199.35 million
• Optionable: No Data
• Beta: 1.82